Jasper Therapeutics Appoints Daniel Adelman, M.D., as Acting Chief Medical Officer
March 23, 2023
Jasper Therapeutics to Present at Upcoming Conferences
March 9, 2023
Jasper Therapeutics Reports Fiscal 2022 Financial Results and Provides a Business Update
March 8, 2023
Jasper Therapeutics Appoints Industry Veteran Vishal Kapoor to its Board of Directors
February 17, 2023
Jasper Therapeutics Announces Positive Follow-up Clinical Data from Investigator-Sponsored Study of Briquilimab Conditioning in Fanconi Anemia Patients at the 2023 Transplantation & Cellular Therapy Meetings of the ASTCT and CIBMTR
February 17, 2023
Jasper Therapeutics Presents Data Supporting Ongoing Development of Briquilimab, its c-Kit Targeting Antibody, at the 2023 Transplantation & Cellular Therapy Meetings of the ASTCT and CIBMTR
February 17, 2023
Jasper Therapeutics Announces Positive Follow-up Clinical Data from Investigator-Sponsored Study of Briquilimab Conditioning in Sickle Cell Disease Patients
February 16, 2023
Jasper Therapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
February 3, 2023
Jasper Therapeutics to Host Investor Conference Call and Webcast on January 31, 2023
January 30, 2023
Jasper Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
January 27, 2023
Displaying 1 - 10 of 16